Skip to content

    Hepatitis Health Center

    Font Size

    Could Hepatitis C Become Rare Disease in 20 Years?

    Newer medications, better screening would fuel the trend, researcher says

    WebMD News from HealthDay

    By Amy Norton

    HealthDay Reporter

    MONDAY, Aug. 4, 2014 (HealthDay News) -- The once tough-to-treat liver infection hepatitis C could become a rare disease in the United States in the next two decades, a new study estimates.

    Hepatitis C, a viral infection that harms the liver, is usually passed through infected blood. For most people, the infection becomes chronic and it can eventually lead to scarring of the liver (cirrhosis) or liver cancer.

    U.S. health officials estimate that over 3 million Americans currently have chronic hepatitis C -- most of whom don't know it because the infection usually causes no symptoms.

    But with recent treatment advances, hepatitis C could become rare by 2036, researchers report in the Aug. 5 issue of the Annals of Internal Medicine.

    "Rare" refers to a disease that affects one in 1,500 people at most, said senior researcher Jagpreet Chhatwal, who conducted the study while at the University of Pittsburgh Graduate School of Public Health. Right now, around one in 100 Americans has chronic hepatitis C.

    But that could quickly shift, since new drugs are changing the landscape of hepatitis C treatment, according to Chhatwal's team.

    "We're in the middle of a very interesting time for hepatitis C patients," said Chhatwal, who is now an assistant professor at the University of Texas MD Anderson Cancer Center in Houston.

    For decades, the only treatment for the disease involved the drug interferon -- which had to be injected and taken for up to a year. It also often caused fatigue and flu-like side effects. After all that, the cure rate was only 40 percent to 50 percent, according to the U.S. Food and Drug Administration.

    But in just the past few years, new drugs have been approved and more are on the way, Chhatwal said.

    One is Sovaldi (sofosbuvir), a pill the FDA approved last December. The treatment lasts just 12 weeks, with no need for interferon injections.

    "There are highly effective drugs becoming available, with a shorter duration of treatment," Chhatwal said. "So, patients should be more amenable to taking them."

    1 | 2 | 3

    Today on WebMD

    Hepatitus C virus
    Types, symptoms and treatments.
    liver illustration
    Myths and facts about this essential organ.
    woman eating apple
    What you need to know.
    doctor and patient
    What causes it?
    Hepatitis C Treatment
    Syringes and graph illustration
    liver illustration
    passport, pills and vaccine
    Scientist looking in microscope
    Fatty Liver Disease
    Digestive Diseases Liver Transplantation
    Picture Of The Liver
    Image Collection